Research programme: cancer vaccines - Voltron Therapeutics
Latest Information Update: 02 Mar 2023
At a glance
- Originator UCSF; Vaccine and Immunotherapy Center
- Developer Massachusetts General Hospital; Voltron Therapeutics
- Class Antineoplastics; Cancer vaccines; Immunotherapies
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 02 Mar 2023 9382396; Updated Deal; Use broader term Cancer as development is in early stage so dormant other lines as suggested by SME; Accordingly make changes in introduction, KDM and in Dev table
- 28 Feb 2023 Preclinical trials in Cancer in USA (Parenteral)
- 12 Jul 2022 Preclinical trials in Anal cancer in USA (Parenteral) (Voltron Therapeutics pipeline, July 2022)